**IPAC Commends Ambitious Phase Down of HFCs and Highlights Imperative to**

**Maximize Benefits for Both Patients and Climate**

The International Pharmaceutical Aerosol Consortium (IPAC) commends the European Commission on ambitious climate action with its proposal for revising the EU F-Gas Regulation. We recognize this represents the culmination of many months of intense effort by the Commission, including public consultation, to evaluate the existing regulation and assess policy options. IPAC understands the Commission’s parallel goals of ensuring continued EU compliance with the Kigali Amendment to the Montreal Protocol and achieving the visions of both the European Green Deal and Climate Law. We trust in the EU co-legislature to ensure the stable global availability of metered dose inhalers (MDIs) that deliver life-saving medicines to millions of patients worldwide while implementing the phase down of F-gases. A holistic approach that centers around effective control of respiratory diseases is best for the patient and the environment.

The EU is a crucial global manufacturer of MDIs for the treatment of life-threatening respiratory illnesses, including asthma and chronic obstructive pulmonary disease (COPD). IPAC’s members acknowledge the impact of propellants in MDIs on the environment and several have publicly announced substantial investments to transition to medical propellants with significantly lower global warming potential (GWP). This transition encompasses a global industry MDI portfolio transformation and is, therefore, complex and time-consuming.

**IPAC and its members stand ready to support the EU legislators to devise the phase-down of medical F-gases in the EU in a way that balances the imperative need for undisrupted patient access to critical medicines for sufficient time to manage the transition to sustainable production by 2030, and for safeguards for EU-based innovation. IPAC has actively engaged in European policy dialogues on HFCs for more than 20 years. We look forward to sharing further perspectives as we review the proposal and assess implications for the MDI sector.**

**About IPAC**

(IPAC) is comprised of AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GSK, Kindeva, Organon and Teva. IPAC members produce MDIs in Europe and supply MDIs to patients worldwide. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC has developed [principles](file:///C%3A%5CUsers%5Cdonam%5CAppData%5CRoaming%5CNRPortbl%5CACTIVE%5CDONAM%5CPrinciples) to help guide policy discussions that reflects the lessons learned in our work on the Montreal Protocol on Substances that Deplete the Ozone Layer.

 For more information, please visit IPAC’s website at [www.IPACinhaler.org](http://www.IPACinhaler.org)

*EU Transparency Register No. 602537137644-70*

*Contacts: Maureen Hardwick (+1 301 980 7837;* *info@ipacinhaler.org**)*

 *Caroline Vogt (+32 473 33 59 65;* *info@ipacinhaler.org**)*